CORRECT (COloRectal cancer treated with REgorafenib or plaCebo after failure of standard Therapy) was a large, international, placebo-controlled, double-blind, randomized (2:1), phase 3 trial that evaluated the efficacy and safety of STIVARGA in patients with mCRC who had progressed after all approved standard therapies (N=760).1, 2
CORRECT trial: 26% of patients received cytotoxic therapy after STIVARGA2, 3
STIVARGA, n (%) | Placebo, n (%) | |
---|---|---|
Systemic anticancer treatment during CORRECT trial follow-up | (n=505) | (n=255) |
Patients with ≥1 medication | 131 (26) | 76 (30) |
Any antineoplastic or immunomodulation agent | 130 (26) | 74 (29) |
Systemic anticancer treatment during CORRECT trial follow-up | STIVARGA, n (%) (n=505) | Placebo, n (%) (n=255) |
---|---|---|
Patients with ≥1 medication | 131 (26) | 76 (30) |
Any antineoplastic or immunomodulation agent | 130 (26) | 74 (29) |
Baseline characteristics2
STIVARGA (n=505) | Placebo (n=255) | |
---|---|---|
Median age, y | 61 | 61 |
Sex | ||
Male | 62% | 60% |
Female | 38% | 40% |
Disease site | ||
Colon | 64% | 68% |
Rectum | 30% | 27% |
Both | 6% | 5% |
Historical KRAS status | ||
Mutated | 54% | 62% |
Race | ||
White | 78% | 79% |
Black or African American | 1% | 3% |
Asian | 15% | 14% |
Other or not specified | 6% | 4% |
ECOG performance status | ||
ECOG PS 0 | 52% | 57% |
ECOG PS 1 | 48% | 43% |